Stay updated with breaking news from Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) saw unusually large options trading activity on Tuesday. Traders acquired 8,333 call options on the company. This represents an increase of 169% compared to the average daily volume of 3,098 call options. Insiders Place Their Bets In other Roivant Sciences news, major shareholder Svf Investments (Uk) Ltd […]
Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) was the recipient of some unusual options trading on Tuesday. Investors acquired 8,333 call options on the company. This represents an increase of 169% compared to the average volume of 3,098 call options. Wall Street Analysts Forecast Growth Several research firms recently issued reports on ROIV. JPMorgan […]
Immunovant (NASDAQ:IMVT – Free Report) had its target price raised by HC Wainwright from $47.00 to $51.00 in a research report released on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. A number of other equities analysts also recently weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on […]
Edge Wealth Management LLC reduced its stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 23.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 134,528 shares of the company’s stock after selling 41,004 shares during the period. Edge Wealth Management LLC’s holdings […]
Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research note released on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $50.00 price objective on the stock. A number of other research analysts have also recently commented on the stock. UBS Group upped their price […]